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Abstract
Aim: To characterize patients with neurogenic bladder (NGB), their treatment
patterns, healthcare resource utilization, and associated costs based on records
from a primary care database in the United Kingdom.
Methods: This was a retrospective, descriptive, observational study of anonymized
data from the Clinical Practice Research Datalink and Hospital Episode Statistics
databases (selection period, 1 January 2004 to 31 December 2016). Adults with a
definitive or probable diagnosis of NGB and ≥1 referral to a urologist were included.
Results: The study cohort included 3913 patients with definitive (n = 363) or
probable (n = 3550) NGB. Patients had a mean of 8.6 (standard deviation [SD],
7.6) comorbidities, and mean Anticholinergic Cognitive Burden Scale score of
6.6 (SD, 5.9). During 12 months’ follow‐up, urinary tract infection (UTI) and
urinary incontinence were the most common complications. Most patients
(92.2%) received ≥1 prescription for an antimuscarinic agent or mirabegron,
and 53.9% of patients received prescriptions for UTI‐specific antibiotics. The
mean number of visits to a general practitioner for any cause was 67.7 (SD, 42.6)
per individual. Almost half (46.7%) of the study cohort visited a specialist during
the 12‐month follow‐up period, and 11.0% had ≥1 hospital admission. Total
mean per patient costs for healthcare resource utilization was £2395.
Conclusions: The burden of illness, healthcare resource needs, and associated
costs among patients with NGB are considerable. Drug prescribing patterns are
consistent with the symptoms and complications of NGB, although increased
awareness of drugs with anticholinergic activity among prescribers may help to
reduce the cumulative anticholinergic burden in this vulnerable population.
© 2019 The Authors. Neurourology and Urodynamics Published by Wiley Periodicals, Inc.
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1 | INTRODUCTION
Neurogenic bladder (NGB) is a general term used to
describe lower urinary tract dysfunction secondary to
neurological disease or central nervous system (CNS)
injury.1 It is thought to affect more than 90% of patients
with spina bifida and spinal cord injury, 50% to 80% of
patients with multiple sclerosis,2 37 to 72% of patients with
Parkinson's disease, and 15% of patients with stroke.3
NGB has many clinical presentations, and the exact
type of urinary tract dysfunction depends on the site,
extent, and evolution of the neurological lesion.4 Urinary
symptoms include frequency, urgency, and urinary incon-
tinence. Patients may also be at risk of urinary tract
infection (UTI), bladder outlet obstruction, and more
serious long‐term sequelae of urosepsis and renal failure.3
For patients with neurological disease, lower urinary tract
dysfunction may be one of the worst aspects of their
condition,4 and symptoms are known to have a marked
negative effect on quality of life.5–7
The goals of treatment for NGB are to restore lower
urinary tract function, achieve or maintain urinary
continence, protect against renal failure, improve quality
of life,8 and minimize the risk of complications, such as
UTI.9 Management strategies include noninvasive con-
servative treatments, catheters, and surgery, as well as
pharmacological therapies.4,8,10 The main pharmacologi-
cal treatments are antimuscarinic agents for neurogenic
detrusor overactivity (NDO) and antibiotics for UTIs.4,8
There is little information on how patients with NGB are
managed in clinical practice,1 and no studies have been
done in the United Kingdom (UK). The primary objective of
this study was to characterize patients with NGB in terms of
demographics, comorbidities, and complications, and to
evaluate their adopted treatment patterns in terms of drug
utilization. The study also assessed healthcare resource
utilization and associated costs in these patients during a
12‐month follow‐up period, based on records from a
primary care database in the UK. These study objectives
were also explored separately according to the underlying
neurological condition, as this may influence symptom
presentation and severity.
2 | PATIENTS AND METHODS
2.1 | Study design and data sources
This was a retrospective, descriptive, observational study
performed using anonymized data from the Clinical Practice
Research Datalink (CPRD) GOLD and Hospital Episode
Statistics (HES) databases. CPRD is a longitudinal primary
care research database that collates medical records from
674 general practices across the UK, and is representative of
the national population in terms of age, sex, and ethnicity.11
It contains information on patient demographics, prescrip-
tions, medical history, diagnostic testing, and secondary care
referrals. HES collates data on inpatient, outpatient, and
accident and emergency admissions from National Health
Service (NHS) hospitals in England; approximately 58% of
practices within the CPRD network have consented to a
linkage scheme enabling patient‐level data to be linked to
other databases including HES.11
The study was conducted in compliance with require-
ments for ensuring the rights of participants in non-
interventional studies.12
2.2 | Study population
The study selection period was from 1 January 2004 to
31 December 2016. Adults aged ≥19 years with a definitive
or probable diagnosis of NGB were included. A definitive
diagnosis required ≥1 diagnosis of NGB or neuropathic
bladder within the study selection period. A probable
diagnosis required a diagnosis of Parkinson's disease,
multiple sclerosis, spinal cord injury, or stroke within the
study selection period; or a diagnosis of spina bifida within
the entire CPRD database, in addition to a subsequent
diagnosis of overactive bladder (OAB) and/or ≥1 prescrip-
tion for an OAB medication. Patients were also required to
have ≥12 months of continuous enrollment in the CPRD
database before the index date (defined as the date of
diagnosis of the neurological condition or, for patients with
spina bifida, the date of OAB diagnosis or OAB drug
prescription, whichever came first), and 12 months
continuous enrollment after diagnosis of OAB or OAB
drug prescription (Figure S1). All patients were required to
have ≥1 referral to a urologist within 12 months before or
12 months after the index date. Patients with idiopathic
OAB, a diagnosis of dementia, or those missing data for age
or sex were excluded. Only patients deemed acceptable for
research by the CPRD, and for whom the study period
occurred during an uninterrupted period where the
practice was deemed “up to standard,”11 were included.
2.3 | Study objectives and endpoints
Full details and definitions of study endpoints are
provided in Table S1. For the primary objectives,
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comorbidities were assessed using a proxy measure, that
is, the number of drug classes prescribed according to
British National Formulary (BNF) headers.13 Complica-
tions considered were UTIs, urinary incontinence, sepsis/
septicemia, urinary retention, obstructive uropathy, renal
failure, and hydronephrosis. Drug utilization at index
date was described by prescriptions for oral OAB drugs,
prescriptions for drugs with anticholinergic activity,
Anticholinergic Cognitive Burden (ACB) Scale score
calculated within 1 month before and after first OAB/
NGB diagnosis or OAB drug prescription date (see
Appendix for details),14,15 and polypharmacy, that is,
the number of substances prescribed according to BNF
headers. Drug utilization during the 12‐month follow‐up
period included prescriptions for oral OAB drugs, OAB
drug combinations (ie, prescriptions overlapping for >30
days), α‐adrenergic antagonists or 5α‐reductase inhibi-
tors, and UTI‐specific antibiotics.
Secondary objectives were to describe healthcare
resource utilization and related costs during the
12‐month follow‐up period. Resource use was defined
as all‐cause general practitioner (GP) consultations,
urological investigations (urodynamics, cystoscopy,
imaging), specialist visits (urologist and gynecologist),
prescriptions for incontinence pads, procedures/sur-
gical interventions (urology), and hospital visits
(urology). Costs were estimated by multiplying each
occurrence of resource use by unit costs derived from
NHS tariffs or other UK‐specific sources16–18
(Table S2).
2.4 | Data analyses
Statistical analyses were descriptive only. Analyses
were performed in the overall study cohort and
stratified by underlying neurological condition (Par-
kinson's disease, multiple sclerosis, spinal cord injury,
stroke, and spina bifida), age (19‐65 vs >65 years), and
sex (female vs male). A sensitivity analysis of the
primary objective was performed using an alternative
definition of patients with probable NGB, that is, the
diagnosis of neurological condition and OAB diag-
nosis/OAB drug prescription could be in any order.
Analyses were performed using SAS, version 9.4 (SAS
Institute, Cary, NC).
2.5 | Ethical approval
Approval for the study protocol was obtained from
the CPRD Independent Scientific Advisory Committee
[protocol: 17_207RMn].
3 | RESULTS
3.1 | Study population
Between 1 January 2004 and 31 December 2016, 19 499
patients with definitive or probable NGB were identified
(Figure 1). After applying the predefined eligibility
criteria, 15 586 (79.9%) patients were excluded, most
commonly because they were not referred to a urologist
(n = 11 946, 61.3%) or because the preindex period was
<12 months (n = 5658, 29.0%). The remaining 3913
(20.1%) patients constituted the study cohort, of whom
363 (9.3%) patients had definitive NGB and 3550 (90.7%)
patients had probable NGB. Patients with probable NGB
were stratified into the following cohorts based on their
underlying neurological condition (note: groups were not
mutually exclusive): stroke (n = 1720); multiple sclerosis
(n = 1029); Parkinson's disease (n = 713); spina bifida
(n = 180); and spinal cord injury (n = 41). Approximately
50% of the study cohort (n = 2330 patients) had data
linked to the HES database.
The study cohort had a mean age of 61.7 (standard
deviation [SD], 16.3) years, and 59.6% were men (Table 1).
Comorbidities, assessed by the number of different drug
classes prescribed, were common (mean 8.6 [SD, 7.6]), and
occurred more frequently among older than younger
patients (mean 10.0 [SD, 7.3] vs 7.4 [SD, 7.7]) (Table S3).
3.2 | Drug utilization
Two‐thousand one‐hundred and thirty‐seven (54.6%)
patients received ≥1 prescription for drugs with antic-
holinergic activity before the index period (Table 1). The
drugs with at least partial anticholinergic activity were
not solely the OAB‐therapeutic antimuscarinics. Those
most commonly prescribed were solifenacin (8.5%),
warfarin (weakly anticholinergic, 7.9%), furosemide
(weakly anticholinergic, 7.6%), amitriptyline (7.2%),
oxybutynin (7.1%), codeine/paracetamol (weakly antic-
holinergic, 6.9%), and tolterodine (6.0%) Table S4). The
mean ACB score, a measure of cumulative anticholiner-
gic burden, was 6.6 (SD, 5.9) in the study cohort, and
ranged from 2.9 (definite NGB cohort) to 7.6 (stroke
cohort) (Table 1), but was similar between age and sex
subgroups (Table S3).
At index date, 3175 (81.1%) patients were receiving an
oral antimuscarinic agent or mirabegron. The most
commonly prescribed agents were solifenacin (n = 992,
25.4%), oxybutynin immediate‐release (n = 803, 20.5%),
tolterodine (n = 723, 18.5%), and oxybutynin extended‐
release (n = 233, 6.0%) (Table 1). Other agents (including
mirabegron) were each prescribed to <5% of patients.
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3.3 | During 12‐month follow‐up
Most of the study cohort (92.2%) received≥ 1 prescription
for an oral antimuscarinic agent or mirabegron over the
12‐month follow‐up period (Table 2); the mean number of
prescriptions per individual was 6.9 (SD, 8.2). A notable
exception was the definitive NGB cohort, where only
29.8% of patients received≥ 1 prescription for these agents
and had an average of 1.6 (SD, 3.5) prescriptions per
individual. The mean cumulative number of days’
supply of OAB drugs was 203 (SD, 211) per individual
in the study cohort. Overall, 312 (8.0%) patients were
prescribed a combination of OAB drugs; the most
common combinations included solifenacin, toltero-
dine, and oxybutynin (Table S5). Approximately half
the cohort (53.9%) had prescriptions for antibiotics to
treat UTIs, and 997 (25.5%) patients had prescriptions
for α‐adrenergic antagonists or 5α‐reductase inhibitors
(Table 2). Drug utilization patterns were similar
between age and sex subgroups, except for α‐adrenergic
antagonists/5α‐reductase inhibitors were prescribed
more often in men (40.7% vs women, 3.0%) and older
patients (37.4% vs younger, 14.5%) (Table S6).
3.4 | Complications
During the 12‐month follow‐up period, 558 (14.3%)
patients had UTIs and 557 (14.2%) patients experienced
urinary incontinence (Table 3). Other complications were
each recorded in <3% of patients. UTIs and urinary
Exclusions
Total 15,586 (79.9%)
Reason(s)*
No referral to urologist within 12-month pre-index and 11,946 (61.3%)
follow-up periods
Less than 12 months prior to index date without NGB/OAB 5658 (29.0%)
diagnosis or OAB-related prescriptions
Less than 12 months’ follow-up 2695 (13.8%)
Diagnosis of dementia within selection period 2439 (12.5%)
Age <19 years at index date 598 (3.1%)
Diagnosis of idiopathic OAB  54 (0.3%)
Study cohort
Eligible patients with NGB during selection period 
(N=3913)
Cohort†
Definitive NGB 363  (9.3%)
Probable NGB
 Parkinson’s disease cohort 713  (18.2%)
 Multiple sclerosis cohort 1029 (26.3%)
 Stroke cohort 1720 (44.0%)
 Spinal cord injury cohort 41 (1.0%)
 Spina bifida cohort 180 (4.6%)
Linked study cohort (HES data)
Eligible patients with NGB during selection period
and with linked HES data
(N=2330)
Cohort†
Definitive NGB 229 (9.8%)
Probable NGB
 Parkinson’s disease cohort 447 (19.2%)
 Multiple sclerosis cohort 627 (26.9%)
 Stroke cohort 988 (42.4%)
 Spinal cord injury cohort 26 (1.1%)
 Spina bifida cohort 105 (4.5%)
Source cohort
Patients with definitive or probable NGB between 
January 1, 2004 and December 31, 2016
(N=19,499)
FIGURE 1 Patient selection flowchart. HES, Hospital Episodes Statistics; NGB, neurogenic bladder; OAB, overactive bladder. *Patients
may have been excluded for more than one reason. †Patients may have been eligible for more than one cohort
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incontinence were the most commonly reported compli-
cations regardless of underlying neurological condition
(Table 3), age, or sex (Table S7).
3.5 | Healthcare resource use and costs
Healthcare resource use and costs during the 12‐month
follow‐up period are presented in Table 4, and by age and
sex in Table S8. All patients had ≥1 GP consultation for
any cause, with a mean of 67.7 (SD, 42.6) visits per
individual over the 12‐month follow‐up period. Patients
with stroke or spinal cord injury visited their GP more
often (76.3 and 75.5, respectively) than other cohorts
(range, 49.9‐69.7). The estimated overall mean cost of GP
consultations was £1448 (SD, £967) per individual.
Overall, 2.5% of the study cohort had ≥1 urodynamic
test (mean cost, £179 [SD, 94] per individual), 8.8%
underwent cystoscopy (£171 [SD, 66] per individual), and
2.1% had urology‐related imaging (£101 [SD, 83] per
individual). Only 14 (0.4%) patients in the study cohort
TABLE 2 Drug utilization during the 12‐mo follow‐up period (overall study cohort and by underlying neurological condition)
Variable
Definitive NGB
(N = 363)
Probable NGB
All
(N = 3913)
PD cohort MS cohort STK cohort SCI cohort SB cohort
(N = 713) (N = 1029) (N = 1720) (N = 41) (N = 180)
Number of oral OAB
drug prescriptions
Mean
(SD)
1.6 (3.5) 7.6 (8.1) 7.1 (7.3) 7.5 (9.1) 9.0 (5.6) 5.0 (6.3) 6.9 (8.2)
Number of oral OAB
drug prescriptions,
n (%)
0 255 (70.2) 11 (1.5) 35 (3.4) 29 (1.7) 4 (9.8) 44 (24.4) 307 (7.8)
1‐4 58 (16.0) 304 (42.6) 412 (40.0) 759 (44.1) 5 (12.2) 63 (35.0) 1571 (40.1)
5‐9 31 (8.5) 160 (22.4) 275 (26.7) 416 (24.2) 13 (31.7) 32 (17.8) 911 (23.3)
10‐14 14 (3.9) 177 (24.8) 243 (23.6) 370 (21.5) 13 (31.7) 37 (20.6) 841 (21.5)
15‐44 5 (1.4) 51 (7.2) 52 (5.1) 117 (6.8) 6 (14.6) 3 (1.7) 231 (5.9)
≥45 0 10 (1.4) 12 (1.2) 29 (1.7) 0 1 (0.6) 52 (1.3)
Cumulative number of
days’ supply of oral
OAB drugs
Mean
(SD)
50.5 (112.5) 221.5
(202.3)
222.2
(188.5)
210.4
(232.6)
273.2
(158.5)
155.0
(155.6)
202.9
(210.9)
Cumulative number of
days’ supply of oral
OAB drugs, n (%)
0‐29 272 (74.9) 101 (14.2) 155 (15.1) 283 (16.5) 7 (17.1) 66 (36.7) 804 (20.5)
30‐119 40 (11.0) 190 (26.6) 250 (24.3) 455 (26.5) 2 (4.9) 34 (18.9) 952 (24.3)
120‐349 32 (8.8) 201 (28.2) 318 (30.9) 515 (29.9) 15 (36.6) 44 (24.4) 1107 (28.3)
350‐549 18 (5.0) 211 (29.6) 292 (28.4) 445 (25.9) 17 (41.5) 36 (20.0) 1003 (25.6)
≥550 1 (0.3) 10 (1.4) 14 (1.4) 22 (1.3) 0 0 47 (1.2)
Oral OAB drug
combination use,
n (%)
Yes 10 (2.8) 58 (8.1) 105 (10.2) 130 (7.6) 2 (4.9) 11 (6.1) 312 (8.0)
Number of
prescriptions for
antibiotics for UTIa
Mean
(SD)
2.7 (4.3) 1.7 (3.3) 2.4 (4.2) 2.1 (3.8) 3.5 (4.9) 3.1 (6.2) 2.2 (4.0)
Number of
prescriptions for
antibiotics for UTIa,
n (%)
0 159 (43.8) 371 (52.0) 473 (46.0) 768 (44.7) 20 (48.8) 71 (39.4) 1803 (46.1)
1‐4 130 (35.8) 261 (36.6) 384 (37.3) 713 (41.5) 8 (19.5) 70 (38.9) 1520 (38.8)
5‐9 42 (11.6) 55 (7.7) 97 (9.4) 144 (8.4) 9 (22.0) 25 (13.9) 352 (9.0)
10‐14 23 (6.3) 22 (3.1) 49 (4.8) 54 (3.1) 2 (4.9) 9 (5.0) 155 (4.0)
15‐19 9 (2.5) 4 (0.6) 26 (2.5) 40 (2.3) 2 (4.9) 4 (2.2) 81 (2.1)
≥20 0 0 0 1 (0.1) 0 1 (0.6) 2 (0.1)
Number of
α‐adrenergic
antagonists or 5‐ARI
prescriptionsb
Mean
(SD)
0.8 (2.9) 4.3 (9.8) 0.6 (2.4) 4.3 (9.5) 0.6 (3.8) 0.6 (2.7) 2.9 (8.0)
Number of
α‐adrenergic
antagonists or 5‐ARI
prescriptions,b n (%)
0 321 (88.4) 448 (62.8) 958 (93.1) 1107 (64.4) 39 (95.1) 165 (91.7) 2916 (74.5)
1‐4 14 (3.9) 63 (8.8) 18 (1.7) 126 (7.3) 1 (2.4) 6 (3.3) 223 (5.7)
5‐9 16 (4.4) 76 (10.7) 26 (2.5) 177 (10.3) 0 4 (2.2) 296 (7.6)
10‐14 10 (2.8) 76 (10.7) 23 (2.2) 190 (11.0) 0 4 (2.2) 300 (7.7)
15‐19 2 (0.6) 41 (5.8) 4 (0.4) 102 (5.9) 1 (2.4) 1 (0.6) 151 (3.9)
≥20 0 9 (1.3) 0 18 (1.0) 0 0 27 (0.7)
Abbreviations: 5‐ARI, 5α‐reductase inhibitors; MS, multiple sclerosis; NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson's disease; SB, spina
bifida; SCI, spinal cord injury; SD, standard deviation; STK, stroke; UTI, urinary tract infection.
aTrimethoprim, ciprofloxacin, nitrofurantoin, amoxicillin, amoxicillin/clavulanic acid at any dosage.
bDoxazosin, tamsulosin, alfuzosin, terazosin, finasteride, dutasteride at any dosage.
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were prescribed incontinence pads (mean cost, £40 [SD,
47] per individual). Almost half of the study cohort
(46.7%) visited a specialist (urologist or gynecologist) over
the 12‐month follow‐up period, with a mean 2.3 (SD, 1.7)
visits at a mean cost of £253 (SD, 186) per individual;
most visits (90.8%) were to a urologist rather than a
gynecologist (Table 4). At least one procedure or surgical
intervention was performed in 5.7% of the study cohort at
a mean cost of £2285 (SD, £3919) per individual. Overall,
11.0% (n = 431) of the study cohort were hospitalized for
a mean of 12.5 days during the 12‐month follow‐up
period; 17.4% (75 of 431) of hospitalized patients were
admitted after renal failure. Hospital admissions were
more common in the definite NGB and spinal cord injury
cohorts (20.1% and 19.5%, respectively) compared to
other cohorts (range, 6.7 to 12.0%), but were similar
between age and sex subgroups. The mean costs for
hospitalization were £6256 (SD, £13,473) per individual.
3.6 | Sensitivity analysis
The primary objectives of the study were reanalyzed
using an alternative definition for patients with probable
NGB (ie, diagnoses for the underlying neurological
condition or OAB diagnosis/OAB drug prescription could
be in any order). The results were similar to those of the
base‐case analysis (data not shown).
4 | DISCUSSION
This study provides detailed descriptive information
about patients with NGB and, to our knowledge, is
the first study to characterize this patient population in
the UK. Over the 13‐year study selection period, we
identified 363 patients with a definitive diagnosis of NGB
and a further 3550 patients with probable NGB based on
proxy inclusion criteria. The high number of probable
cases suggests that many patients with NGB may not
be formally diagnosed in the UK, and is possibly
indicative of low awareness of the condition among
GPs and neurologists, or limitations in data coding
practices. A notable feature of patient selection in our
study was the requirement for at least one referral to a
urologist, a criterion intended to reduce the risk of
including non‐NGB patients. This requirement led to the
exclusion of many patients (61%) from the original source
cohort, suggesting that our final study cohort may be an
underestimate of the true size of the NGB population. It
also highlights that primary care providers may take
responsibility for much of the care of patients with NGB.
We recognize also that the requirement for a urologist
referral may have removed some patients with a lower
burden of illness from our study, and suggest that this
should be considered when interpreting the data.
Our findings suggest that patients with NGB have
multiple comorbidities and complications. Urinary
incontinence and UTIs were common, and more than
half (54%) of our study population received prescriptions
for UTI‐specific antibiotics. Serious complications (renal
failure and sepsis) were rare and affected less than 1% of
patients each, although observation of these events is
likely limited by the short 12‐month follow‐up period. A
similar spectrum of complications was documented in a
large US claims database study of patients with NGB
(n = 46 271),1 albeit at much higher frequencies than in
our study. For example, UTIs, urinary retention, and
sepsis/septicemia were reported in 33%, 14%, and 4% of
TABLE 3 Complications during the 12‐mo follow‐up period (overall study cohort and by underlying neurological condition)
Complication,a
n (%)
Definitive
NGB(N= 363)
Probable NGB
All(N= 3913)
PD
cohort
(N= 713)
MS cohort
(N= 1029)
STK cohort
(N= 1720)
SCI
cohort
(N= 41)
SB
cohort
(N= 180)
Urinary tract
infection
71 (19.6) 72 (10.1) 153 (14.9) 237 (13.8) 14 (34.1) 35 (19.4) 558 (14.3)
Urinary incontinence 31 (8.5) 119 (16.7) 141 (13.7) 260 (15.1) 2 (4.9) 21 (11.7) 557 (14.2)
Urinary retention 13 (3.6) 21 (2.9) 19 (1.8) 45 (2.6) 0 1 (0.6) 96 (2.5)
Sepsis/septicemia 4 (1.1) 5 (0.7) 7 (0.7) 18 (1.0) 1 (2.4) 2 (1.1) 34 (0.9)
Renal failure (acute
or other)
13 (3.6) 5 (0.7) 2 (0.2) 7 (0.4) 0 5 (2.8) 27 (0.7)
Hydronephrosis 6 (1.7) 3 (0.4) 1 (0.1) 3 (0.2) 0 3 (1.7) 14 (0.4)
Obstructive uropathy 0 0 0 0 0 1 (0.6) 1 (0.0)
Abbreviations: MS, multiple sclerosis; NGB, neurogenic bladder; PD, Parkinson's disease; SB, spina bifida; SCI, spinal cord injury; STK, stroke.
aEach complication was identified from medical records using prespecified read codes.
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patients in the US study,1 respectively, compared with
14%, 2%, and 1% in our study. As key design features,
including duration of follow‐up, were similar between
studies, the reason for the marked disparity between
reporting rates is unknown.
The drug utilization patterns documented in our study
were consistent with current NGB treatment guide-
lines.4,8 Antimuscarinic agents are recommended as
first‐line pharmacological therapy for NDO,4,8 and most
(92%) patients in our study had ≥1 prescription for an
antimuscarinic agent or mirabegron over the 12‐month
study period. It is possible that this rate may be elevated
by the requirement for an OAB prescription for inclusion
into the probable NGB cohort; the prescribing rate was
lower (30%) in the definite NGB cohort whose selection
was based on NGB diagnosis alone. It is also notable that
some of this prescribing were off‐label as several of these
agents do not have marketing authorization for the
treatment for NGB in the UK. Antimuscarinic combina-
tions, also supported by treatment guidelines,8 were
prescribed in 8% of patients. Mirabegron was prescribed
infrequently (about 1% of patients), although its use in
NGB is not currently supported by treatment guide-
lines4,8 and it was introduced in the UK only towards
the end of the study selection period. One‐quarter of the
study cohort also received prescriptions for α‐adrenergic
antagonists or 5α‐reductase inhibitors; α‐adrenergic
antagonists are recommended for bladder outlet resis-
tance in NGB4,8 and may have contributed to some of this
prescribing.
Neurological patients may be particularly susceptible
to the unwanted central actions of some drugs because
the integrity of the blood‐brain barrier can be disrupted
by the disease process.2,9 The National Institute for
Health and Care Excellence (NICE) suggests that the
potential for CNS‐related side effects with agents known
to cross the blood‐brain barrier (eg, oxybutynin) should
be considered when prescribing an antimuscarinic agent
for NGB10 yet, in our study, oxybutynin was prescribed
to approximately 25% of patients. Furthermore, other
drugs with anticholinergic activity and the potential for
causing negative cognitive effects were commonly
prescribed, and the cumulative ACB in our study
population at baseline was high (mean ACB score 6.6,
where a score ≥3 is considered to be clinically
relevant14). The implications of overprescribing drugs
with anticholinergic effects are well documented; each
1‐point increase on the ACB scale is associated with a
13% increase in the risk of cognitive impairment, and an
11% increase in the likelihood of inpatient admission.19
Increased prescriber awareness of drugs with antic-
holinergic effects may help to reduce the risk of
unwanted CNS events in these patients.
High levels of healthcare resource use were evident in
our study population. On average, patients visited or
made contact with their general practice 68 times over a
12‐month period. Patients also visited a specialist twice
on average and had one urology‐related hospital admis-
sion and one surgical procedure over a 12‐month period.
An unexpected finding was the very low rate of
prescribing for incontinence pads (0.4%), which was at
odds with the reporting rate for urinary incontinence
(14%) in our study. It seems likely that patients purchased
pads as an out‐of‐pocket expense rather than obtaining
them by prescription. After applying unit costs from
standard UK sources, the average costs for healthcare
resource utilization (excluding drugs) across the overall
study cohort was an estimated £2395 per individual over
12 months. To our knowledge, this is first study to
provide a comprehensive evaluation of healthcare‐related
costs in patients with NGB, as previous cost‐of‐illness
studies have focused on emergency department admis-
sions alone.20,21
The patient selection criteria adopted in our study (ie,
proxy criteria to identify probable cases of NGB [based on
diagnosis of a neurological condition plus a diagnosis of
OAB/prescription of OAB drug] and requirement for a
urologist referral) may introduce selection bias and limit
the generalizability of our findings. However, when
studying a condition such as NBG with proposed under-
diagnoses and low awareness in some clinician groups, the
selection process must adopt an appropriate level of
specificity and sensitivity. Further, the drug choices
reported are likely to have been influenced by NICE and
may differ from other countries. The main limitations of
our study were its retrospective design and the absence of
a control cohort to compare outcomes against. Cost
estimates are likely to be conservative as the unit costs
and NHS tariffs used in our study did not capture all
relevant direct medical costs (eg, theater time), and drug
acquisition costs were also not considered.
We suggest that future studies should include a longer
follow‐up period and include less common neurological
conditions associated with NGB (eg, cerebral palsy).
Physician surveys, to better understand the rationale for
prescribing decisions, as well as studies of cognitive
function in patients receiving antimuscarinic agents
would also be of interest.
5 | CONCLUSIONS
Our findings suggest that NGB may be underrecognized
among primary care providers in the UK. The burden of
illness, healthcare needs and associated costs evident in
our study population were considerable. Drug prescribing
10 | JAGGI ET AL.
patterns were consistent with the symptoms and com-
plications of NGB, although increased awareness and
reduced prescribing of agents with anticholinergic effects
may help to improve health outcomes in this vulnerable
patient population.
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